Larazotide for Celiac Disease and Gluten Exposure

Candidate profile

Adults with confirmed celiac disease (positive tissue transglutaminase antibodies, confirmed by duodenal biopsy showing villous atrophy) who are adherent to a gluten-free diet but continue to experience symptoms — a population that represents a significant unmet medical need. Studies show that 30-50% of celiac patients on a strict gluten-free diet continue to report symptoms including bloating, abdominal pain, fatigue, and brain fog, often attributed to inadvertent gluten contamination in supposedly gluten-free foods, cross-contamination during dining out, or trace gluten exposure in social settings.

This use case specifically targets two scenarios: (1) ongoing symptom management for celiac patients who experience persistent symptoms despite dietary adherence, likely due to unavoidable low-level gluten contamination in the food supply, and (2) prophylactic protection before situations with elevated cross-contamination risk — restaurant meals, travel, social dining events — where strict gluten avoidance is difficult to guarantee.

Larazotide is not intended as a replacement for a gluten-free diet. It is designed as an adjunctive protective measure that reduces the intestinal damage caused by gluten exposure when complete avoidance fails. Non-celiac gluten sensitivity may also respond, though the clinical evidence is specific to celiac disease.

Approach

Larazotide acetate (previously designated AT-1001) is a synthetic octapeptide (8 amino acids) derived from Vibrio cholerae zonula occludens toxin (Zot). While Zot opens tight junctions to cause the intestinal permeability increase associated with cholera, Larazotide is an antagonist of this pathway — it blocks the zonulin receptor on intestinal epithelial cells, preventing tight junction opening. This is directly relevant to celiac disease because gliadin (the immunogenic component of gluten) triggers zonulin release from the intestinal epithelium, which opens tight junctions and allows gliadin peptides to access the lamina propria where they encounter the immune system and trigger the characteristic inflammatory response.

By blocking the zonulin-mediated tight junction opening, Larazotide prevents gliadin from reaching the immune cells that drive celiac pathology. The gluten peptides pass through the gut lumen without gaining paracellular access, and the immune cascade that causes villous atrophy, crypt hyperplasia, and symptoms is not triggered. This is an elegant mechanistic approach because it addresses the gatekeeping step of celiac pathology — intestinal permeability — rather than attempting to suppress the downstream immune response.

Larazotide acts locally in the gut and has minimal systemic absorption, which contributes to its favorable safety profile observed across clinical trials.

Protocol design

Primary peptide: Larazotide acetate, 0.5 mg per dose (the dose that demonstrated optimal efficacy in Phase 2b trials — notably, this was the lowest dose tested, and higher doses of 1 mg and 2 mg showed less benefit, suggesting an inverted dose-response consistent with receptor saturation at the local mucosal level)

Route: Oral capsule

Frequency: Three times daily, before meals

Timing: Administer 15 minutes before each major meal. The timing is critical — Larazotide must be present in the intestinal lumen before gluten arrives so that zonulin receptors are occupied and tight junctions are protected when gliadin begins triggering zonulin release. Taking Larazotide after gluten exposure provides minimal benefit because the tight junctions have already opened.

Ongoing daily protocol (for chronic symptom management):

Three times daily before meals, continuously, as part of the standard management regimen alongside a gluten-free diet. This addresses the estimated 50-150 mg of gluten that even the most vigilant celiac patients inadvertently consume daily from contaminated gluten-free products, shared cooking surfaces, and trace amounts in processed foods.

Prophylactic protocol (for high-risk exposure situations):

Take 0.5 mg before the high-risk meal. For extended high-risk periods (multi-day travel, holiday gatherings), maintain the three-times-daily schedule throughout the exposure period plus 24 hours afterward, as residual gluten may continue transiting through the small intestine after the last exposure.

Adjunctive support — BPC-157: 250-500 mcg oral, twice daily. For celiac patients with evidence of ongoing mucosal damage (elevated tissue transglutaminase antibodies despite dietary adherence), BPC-157 provides complementary mucosal healing support through angiogenesis promotion and growth factor upregulation at the intestinal epithelium. Larazotide prevents new damage; BPC-157 supports repair of existing damage.

Adjunctive support — KPV: 200-500 mcg oral, once daily. KPV (lysine-proline-valine, derived from alpha-MSH) inhibits NF-kB-mediated inflammation in colonocytes and small intestinal epithelial cells, addressing the inflammatory component of celiac disease that persists even on a gluten-free diet.

Expected timeline

Days 1-7: Reduction in daily GI symptom burden. The Phase 2b trial (CeliAction study) demonstrated significant improvement in the Celiac Disease Gastrointestinal Symptom Rating Scale (CeD-GSRS) with 0.5 mg Larazotide compared to placebo. Clinically, patients report less bloating after meals, reduced abdominal pain, and fewer episodes of diarrhea within the first week. These improvements reflect reduced paracellular gluten transit and decreased immune activation from daily inadvertent gluten exposure.

Weeks 2-4: Symptom improvements consolidate. The intermittent symptom spikes that celiac patients experience (often attributed to accidental gluten exposure) become less frequent and less severe. Fatigue and brain fog episodes associated with gluten exposure may diminish, as these are likely driven by cytokine release from the intestinal immune response that Larazotide is now preventing.

Weeks 4-8: If tissue transglutaminase (tTG) antibodies were elevated at baseline (indicating ongoing mucosal damage from gluten exposure despite dietary adherence), they may begin trending downward as reduced gluten access to the lamina propria decreases the autoimmune stimulus driving antibody production. Lactulose-mannitol testing (if performed) should show improved intestinal permeability ratios.

Weeks 8-12: Broader quality-of-life improvements. Reduced anxiety around food choices and social dining situations as patients experience that low-level gluten exposures no longer trigger symptom flares. Nutritional absorption may improve if villous recovery is occurring, potentially reflected in improved iron, folate, and vitamin D levels that are commonly deficient in celiac patients with ongoing mucosal damage.

Long-term: Larazotide is designed for chronic use alongside a gluten-free diet. The clinical development program is evaluating long-term use, and the safety profile from completed trials (up to 12 weeks of continuous dosing) has shown adverse event rates comparable to placebo. The long-term vision is a daily medication that provides a protective buffer against the unavoidable gluten contamination that makes celiac disease management so difficult.

Monitoring and adjustments

• Celiac Disease Gastrointestinal Symptom Rating Scale (CeD-GSRS) — weekly during the first 8 weeks, then monthly (this is the primary outcome measure used in the clinical trials)
• Tissue transglutaminase IgA (tTG-IgA) at baseline, week 8, and week 16 — the key serological marker of celiac disease activity
• Deamidated gliadin peptide antibodies (DGP-IgA) at baseline and week 16 — may be more sensitive to recent gluten exposure than tTG
• Lactulose-mannitol intestinal permeability test at baseline and week 12 (if available)
• Nutrient status: serum ferritin, folate, vitamin B12, vitamin D, zinc — at baseline and week 12. Improvement suggests better absorptive capacity from mucosal recovery.
• Symptom diary — daily log of GI symptoms, extra-intestinal symptoms (fatigue, headache, joint pain, brain fog), and suspected gluten exposure events
• Quality-of-life assessment: Celiac Disease Quality of Life Survey (CDQ) at baseline, week 8, and week 16

No dose adjustment expected: The 0.5 mg dose has shown the best efficacy-to-dose ratio in clinical trials. Increasing the dose above 0.5 mg did not improve outcomes in Phase 2b. If inadequate response occurs, the issue is more likely related to the magnitude of gluten exposure (consider further dietary audit) or non-gluten triggers for symptoms (lactose intolerance, FODMAP sensitivity, small intestinal bacterial overgrowth) rather than insufficient Larazotide dosing.

When to stop or escalate

• No symptom improvement after 4 weeks of consistent use: Reassess whether symptoms are truly gluten-driven. Celiac patients frequently have concurrent functional GI conditions — irritable bowel syndrome overlaps with celiac disease in up to 20% of patients, and FODMAP sensitivity, lactose intolerance (from villous atrophy reducing brush border lactase), and small intestinal bacterial overgrowth (SIBO) can all cause identical symptoms. A comprehensive evaluation for non-celiac symptom generators should be pursued.
• Refractory celiac disease: If tTG antibodies remain persistently elevated and symptoms do not improve despite Larazotide, dietary adherence confirmation (consider a dietitian assessment and possibly gluten immunogenic peptide testing in urine), and exclusion of other diagnoses, consider evaluation for refractory celiac disease — a rare condition where the intestinal immune response has become autonomous and no longer requires gluten exposure to sustain itself. This requires specialist gastroenterology evaluation and possible repeat biopsy.
• New or worsening symptoms: While Larazotide's safety profile is favorable, any new GI symptoms (particularly worsening diarrhea, rectal bleeding, or significant weight loss) warrant gastroenterological evaluation for alternative or concurrent pathology.
• Pregnancy or planned pregnancy: Larazotide has minimal systemic absorption, but limited safety data exist for pregnancy. Discontinue and rely on strict dietary measures until further safety data are available.

Evidence reality check

Larazotide acetate is the most advanced investigational therapeutic specifically designed for celiac disease, having completed Phase 2b clinical trials with positive results and entered Phase 3 development. The Phase 2b CeliAction study (randomized, double-blind, placebo-controlled, 342 patients) demonstrated that 0.5 mg three times daily significantly reduced the CeD-GSRS score compared to placebo in celiac patients on a gluten-free diet. The drug was well-tolerated, with adverse event rates comparable to placebo. Mechanistically, the zonulin pathway in celiac disease is well-characterized through the work of Alessio Fasano and colleagues, providing a strong biological foundation for Larazotide's approach. The Phase 3 program (GRASSROOTS trial) was designed to confirm these findings in a larger population. This is one of the few peptides in the research space that has advanced through a rigorous pharmaceutical development pathway with FDA oversight, IND filing, and formal clinical trials — placing it on much stronger evidentiary ground than most peptides discussed in educational contexts. The primary uncertainty is whether Phase 3 results will confirm Phase 2b findings and whether the inverted dose-response (lower dose outperforming higher doses) is reproducible.